Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
07 Décembre 2023 - 1:00PM
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA
medicines company committed to delivering life-changing treatments
for people battling devastating diseases, announced today the
pricing of its previously announced underwritten public offering of
20,000,000 of its ordinary shares at a price to the public of $5.00
per ordinary share. Gross proceeds to Wave Life Sciences from the
offering are expected to be approximately $100 million, before
deducting underwriting discounts and commissions and offering
expenses. All of the ordinary shares in the offering are being sold
by Wave Life Sciences. In addition, Wave Life Sciences has granted
the underwriters a 30-day option to purchase up to an additional
3,000,000 of its ordinary shares on the same terms and conditions.
The offering is expected to close on or about December 11, 2023,
subject to customary closing conditions.
J.P. Morgan and Leerink Partners are acting as joint
book-running managers for the offering. Mizuho and Truist
Securities are acting as book-runners and H.C. Wainwright &
Co. and Raymond James are acting as co-managers for the
offering.
The offering is being made only by means of a prospectus and
related prospectus supplement forming part of a shelf registration
statement that was previously filed with and declared effective by
the Securities and Exchange Commission (“SEC”). The preliminary
prospectus supplement and accompanying base prospectus relating to
the offering were filed with the SEC on December 6, 2023. The final
prospectus supplement and the accompanying prospectus will be filed
with the SEC and will be available on the SEC’s website located at
http://www.sec.gov, copies of which may be obtained, when
available, from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; or from Leerink Partners LLC,
Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, or by telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@leerink.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA
medicines company committed to delivering life-changing treatments
for people battling devastating diseases. Wave aspires to develop
best-in-class medicines across multiple therapeutic modalities
using PRISM, the company’s proprietary discovery and drug
development platform that enables the precise design, optimization
and production of stereopure oligonucleotides. Driven by a resolute
sense of urgency, the Wave team is targeting a broad range of
genetically defined diseases so that patients and families may
realize a brighter future.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Forward-looking statements include
statements regarding the closing of the public offering of ordinary
shares. These statements are subject to various risks and
uncertainties, actual results could differ materially from those
projected and Wave cautions investors not to place undue reliance
on the forward-looking statements in this press release. These
risks and uncertainties include, without limitation, risks and
uncertainties related to satisfaction of customary closing
conditions related to the public offering. There can be no
assurance that Wave will be able to complete the public offering on
the anticipated terms, or at all. Any forward-looking statements in
this press release are based on management’s current expectations
and beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, the risks and uncertainties described in the section
entitled “Risk Factors” in Wave’s preliminary prospectus supplement
related to the proposed offering filed with the SEC on December 6,
2023 and Wave’s most recent Annual Report on Form 10-K filed with
the SEC, as amended, and in other filings Wave makes with the SEC
from time to time. Wave undertakes no obligation to update the
information contained in this press release to reflect subsequently
occurring events or circumstances.
Investor Contact: Kate Rausch+1
617-949-4827krausch@wavelifesci.com
Media Contact: Alicia Suter +1
617-949-4817asuter@wavelifesci.com
Wave Life Sciences (NASDAQ:WVE)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Wave Life Sciences (NASDAQ:WVE)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024